Fort Brown Dialysis is a medicare approved dialysis facility center in Brownsville, Texas and it has 13 dialysis stations. It is located in Cameron county at 2000 Boca Chica Blvd, Brownsville, TX, 78521. You can reach out to the office of Fort Brown Dialysis at (956) 544-1158. This dialysis clinic is managed and/or owned by Davita. Fort Brown Dialysis has the following ownership type - Profit. It was first certified by medicare in May, 2016. The medicare id for this facility is 672777 and it accepts patients under medicare ESRD program.
| Name | Fort Brown Dialysis |
|---|---|
| Location | 2000 Boca Chica Blvd, Brownsville, Texas |
| No. of Dialysis Stations | 13 |
| Medicare ID | 672777 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2000 Boca Chica Blvd, Brownsville, Texas, 78521 | |
| (956) 544-1158 | |
| Not Available |
News Archive
Recent research supports the ability of some herbal agents, taken orally or applied topically, to prevent sunburn and limit the damage caused by excessive exposure to ultraviolet (UV) light.
When the body encounters an infection, a molecular signaling system ramps up the body's infection-fighting system to produce more white blood cells to attack invading bacteria.
The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.
President Obama signed into law the bipartisan Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) on July 9.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
› Verified 6 days ago
| NPI Number | 1285037168 |
| Organization Name | Fort Brown Dialysis |
| Doing Business As | Afton Dialysis Llc |
| Address | 2000 Boca Chica Blvd Brownsville, Texas, 78521 |
| Phone Number | (956) 544-1158 |
News Archive
Recent research supports the ability of some herbal agents, taken orally or applied topically, to prevent sunburn and limit the damage caused by excessive exposure to ultraviolet (UV) light.
When the body encounters an infection, a molecular signaling system ramps up the body's infection-fighting system to produce more white blood cells to attack invading bacteria.
The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.
President Obama signed into law the bipartisan Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) on July 9.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 17 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 29 |
News Archive
Recent research supports the ability of some herbal agents, taken orally or applied topically, to prevent sunburn and limit the damage caused by excessive exposure to ultraviolet (UV) light.
When the body encounters an infection, a molecular signaling system ramps up the body's infection-fighting system to produce more white blood cells to attack invading bacteria.
The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.
President Obama signed into law the bipartisan Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) on July 9.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 41 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 287 |
| Percentage of adult patients getting regular hemodialysis at the center | 90 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Recent research supports the ability of some herbal agents, taken orally or applied topically, to prevent sunburn and limit the damage caused by excessive exposure to ultraviolet (UV) light.
When the body encounters an infection, a molecular signaling system ramps up the body's infection-fighting system to produce more white blood cells to attack invading bacteria.
The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.
President Obama signed into law the bipartisan Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) on July 9.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fort Brown Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 41 |
| Hypercalcemia patient months | 287 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 4 |
| Patients with Serumphosphor | 46 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 18 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 24 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 31 |
News Archive
Recent research supports the ability of some herbal agents, taken orally or applied topically, to prevent sunburn and limit the damage caused by excessive exposure to ultraviolet (UV) light.
When the body encounters an infection, a molecular signaling system ramps up the body's infection-fighting system to produce more white blood cells to attack invading bacteria.
The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.
President Obama signed into law the bipartisan Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) on July 9.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 64 |
| Patient months included in arterial venous fistula and catheter summaries | 274 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 60 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 27 |
News Archive
Recent research supports the ability of some herbal agents, taken orally or applied topically, to prevent sunburn and limit the damage caused by excessive exposure to ultraviolet (UV) light.
When the body encounters an infection, a molecular signaling system ramps up the body's infection-fighting system to produce more white blood cells to attack invading bacteria.
The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.
President Obama signed into law the bipartisan Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) on July 9.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 16 |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
Recent research supports the ability of some herbal agents, taken orally or applied topically, to prevent sunburn and limit the damage caused by excessive exposure to ultraviolet (UV) light.
When the body encounters an infection, a molecular signaling system ramps up the body's infection-fighting system to produce more white blood cells to attack invading bacteria.
The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.
President Obama signed into law the bipartisan Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) on July 9.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
› Verified 6 days ago